Suven Life completes phase I trail for Alzheimer drug

Moneycontrol Bureau

Suven Life Science successfully completed phase I clinical trail of Suvn-502, a new chemical entity for Alzheimer's disease treatment, and said it is filing for Investigational New Drug application with the US Food and Drug Administration.

Suvn-502 will commence into phase II proof of concept clinical trails in human with Alzheimer or Schizophrenia disease after Suven Life gets US FDA approval for IND application, the company said in a press release to the stock exchanges Wednesday.

If everything is successful during clinical trail, the likely launch year will be 2015, Suven Life Science spokesperson told Moneycontrol.com.

The drug, which was already tested in human during the phase I trail in Switzerland, has shown to be very safe at all doses and durations tested with excellent bioavailability, the company said.

Suvn-502 will be used to treat central nervous system disorders like Alzheimer